Anavex Life Sciences Corp. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
42 Pages - GMD12080
$1,500.00

Summary

Global Markets Direct’s, ‘Anavex Life Sciences Corp. - Product Pipeline Review - 2014’, provides an overview of the Anavex Life Sciences Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Anavex Life Sciences Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Anavex Life Sciences Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Anavex Life Sciences Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Anavex Life Sciences Corp.’s pipeline products

Reasons to buy

- Evaluate Anavex Life Sciences Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Anavex Life Sciences Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Anavex Life Sciences Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Anavex Life Sciences Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Anavex Life Sciences Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Anavex Life Sciences Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Anavex Life Sciences Corp. Snapshot 5
Anavex Life Sciences Corp. Overview 5
Key Information 5
Key Facts 5
Anavex Life Sciences Corp. - Research and Development Overview 6
Key Therapeutic Areas 6
Anavex Life Sciences Corp. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Anavex Life Sciences Corp. - Pipeline Products Glance 11
Anavex Life Sciences Corp. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Anavex Life Sciences Corp. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Anavex Life Sciences Corp. - Drug Profiles 14
ANAVEX-2-73 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AF-710B 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Anavex Plus 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ANAVEX-1-41 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ANAVEX-1005 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ANAVEX-1007 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ANAVEX-1066 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ANAVEX-1079 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ANAVEX-1519 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ANAVEX-19-144 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Anavex Life Sciences Corp. - Pipeline Analysis 27
Anavex Life Sciences Corp. - Pipeline Products by Target 27
Anavex Life Sciences Corp. - Pipeline Products by Route of Administration 29
Anavex Life Sciences Corp. - Pipeline Products by Molecule Type 30
Anavex Life Sciences Corp. - Pipeline Products by Mechanism of Action 31
Anavex Life Sciences Corp. - Recent Pipeline Updates 33
Anavex Life Sciences Corp. - Dormant Projects 38
Anavex Life Sciences Corp. - Company Statement 39
Anavex Life Sciences Corp. - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Anavex Life Sciences Corp., Key Information 5
Anavex Life Sciences Corp., Key Facts 5
Anavex Life Sciences Corp. - Pipeline by Indication, 2014 7
Anavex Life Sciences Corp. - Pipeline by Stage of Development, 2014 9
Anavex Life Sciences Corp. - Monotherapy Products in Pipeline, 2014 10
Anavex Life Sciences Corp. - Phase I, 2014 11
Anavex Life Sciences Corp. - Preclinical, 2014 12
Anavex Life Sciences Corp. - Pipeline by Target, 2014 28
Anavex Life Sciences Corp. - Pipeline by Route of Administration, 2014 29
Anavex Life Sciences Corp. - Pipeline by Molecule Type, 2014 30
Anavex Life Sciences Corp. - Pipeline Products by Mechanism of Action, 2014 32
Anavex Life Sciences Corp. - Recent Pipeline Updates, 2014 33
Anavex Life Sciences Corp. - Dormant Developmental Projects,2014 38

List of Figures
Anavex Life Sciences Corp. - Pipeline by Top 10 Indication, 2014 7
Anavex Life Sciences Corp. - Pipeline by Stage of Development, 2014 9
Anavex Life Sciences Corp. - Monotherapy Products in Pipeline, 2014 10
Anavex Life Sciences Corp. - Pipeline by Top 10 Target, 2014 27
Anavex Life Sciences Corp. - Pipeline by Top 10 Route of Administration, 2014 29
Anavex Life Sciences Corp. - Pipeline by Top 10 Molecule Type, 2014 30
Anavex Life Sciences Corp. - Pipeline Products by Top 10 Mechanism of Action, 2014 31

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax